 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > OSI Pharmaceuticals, Inc.
 |
OSI Pharmaceuticals, Inc. |
 |
 |
 |
PROFILE |
 |
OSI Pharmaceuticals is hot on the trail of some of the most wanted genes in medicine. It has identified some 50 gene targets for which it is developing drug candidates. These candidates include treatments for cancer, diabetes, asthma, high cholesterol, heart disease, and other disorders. Its lead candidate, OSI-774, has demonstrated the ability to block tumor growth hormones in ovarian, head and neck, and certain lung cancers. OSI is working with such companies and organizations as Aventis, Sankyo, Tanabe Seiyaku, and Vanderbilt University. Through its Anaderm Research joint venture with Pfizer and New York University, the company is developing cosmeceuticals to treat hair loss and wrinkles.
COMPETITION |
 |
Axys Pharmaceuticals, Inc. (AXPH)
Johnson & Johnson (JNJ)
Merck & Co., Inc. (MRK)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: September
2000 Sales (mil.): 28.70
1-Yr. Sales Growth: 26.4%
Employees: 221
Revenue per employee: $129,864.25
KEY PEOPLE |
 |
Colin Goddard
CEO
Robert L. Van Nostrand
CFO
CONTACT INFO |
 |
106 Charles Lindbergh Blvd.
Uniondale, NY 11553
US
Phone: 516-222-0023
Fax: 516-222-0114
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |